Results 161 to 170 of about 31,381 (233)

Correction: An integrative analysis of transcriptome, methylome and single-cell RNA sequencing data identifies UBE2H as a marker of oxaliplatin resistance in colorectal cancer. [PDF]

Cancer Cell Int
Fang J, Zhu Q, Hong B, Li X, Wang H.
europepmc   +1 more source

Deep Learning Predicts Imminent Tumor Progression in Advanced Pancreatic Adenocarcinoma Using Serial CT Scans During Chemotherapy

MedComm, Volume 7, Issue 8, August 2026.
A spatiotemporal deep learning model combining serial CT scans and baseline clinical data predicts tumor progression at the next follow‐up visit in advanced PDAC. The model achieved robust performance across internal, external, and prospective cohorts (AUC: 0.74–0.77). This noninvasive approach enables earlier identification of imminent progression and
Jun Cheng, Yize Mao, Shuxiang Huang, Xiaotong Tan, Xiaoping Yi, Xiaoying Du, Qiulin Liu, Jianyao Zhou, Rong Huang, Weijie Chen, Rong Zhang, Lizhi Liu, Wufeng Xue, Ruobing Huang, Youhui Qian, Dong Ni, Wenjun Mao, Tao Qin, Shengping Li, Qiuxia Yang   +19 more
wiley   +1 more source

Cigarette smoke extract promotes metastasis and oxaliplatin resistance in colon adenocarcinoma through GDF15/ERBB2/AKT pathway. [PDF]

Eur J Med Res
Jiang W, Wang Y, Wang WJ, Zhou BC, Hu XS, Xu AM.   +5 more
europepmc   +1 more source

Turning Cold Tumors Into Hot Tumors: Implications for Cancer Therapy

MedComm, Volume 7, Issue 8, August 2026.
Barrier‐defined strategies for cold‐to‐hot tumor conversion. Cold tumors include immune‐desert and immune‐excluded states marked by poor antigen visibility, limited T‐cell priming, stromal or vascular exclusion, metabolic stress and suppressive immune programs.
Xiao Ge, Dong Han, Jing Wang, Xinyu Dai, Chen Ma, Feihong Chen   +5 more
wiley   +1 more source

Overexpression of Protein Kinase C iota as a prognostic marker and its role in oxaliplatin resistance in colorectal cancer. [PDF]

BMC Gastroenterol
Liao X, Liu M, Hong C, Liu Y, Li Q, Chen Y, Zhang T, Chen H, Fu S.   +8 more
europepmc   +1 more source

Caffeic Acid Intervention Slows Cancer Cell Growth While Reversing the Th2‐Biased Immune Balance in Human Colorectal Cancer HT‐29 Cell‐Bearing Mice

Molecular Nutrition &Food Research, Volume 70, Issue 16, 27 August 2026.
Possible immunomodulatory effects of caffeic acid on BALB/cnu mice subcutaneously loaded with HT‐29 cells. ABSTRACT The effects of caffeic acid (CA) intervention on the relationship between human colorectal cancer (CRC) HT‐29 cell growth and Th1/Th2 immune balance in vivo are not fully understood.
Hsuan‐Yin Chen, Chang‐Lin Lin, Chou‐Chen Chen, Jin‐Yuarn Lin   +3 more
wiley   +1 more source

An integrative analysis of transcriptome, methylome and single-cell RNA sequencing data identifies UBE2H as a marker of oxaliplatin resistance in colorectal cancer. [PDF]

Cancer Cell Int
Fang J, Zhu Q, Hong B, Li X, Wang H.
europepmc   +1 more source

Addressing the distressing: Pancreatic enzyme replacement therapy mitigates abdominal symptoms and weight loss during chemotherapy for advanced pancreatic cancer: A prospective study

Nutrition in Clinical Practice, Volume 41, Issue 4, Page 1157-1165, August 2026.
Abstract Background Pancreatic enzyme insufficiency (PEI) contributes to symptom burden and malnutrition in advanced pancreatic cancer (aPC). We aimed to evaluate the impact of pancreatic enzyme replacement therapy (PERT) on symptom burden and weight during chemotherapy.
Pamela N. Klassen, Christina A. Kim, Jessica Kasnik, Michael B. Sawyer, Sunita Ghosh, Vickie Baracos, Vera C. Mazurak   +6 more
wiley   +1 more source

A Novel Combination Therapy for Human Oxaliplatin-resistant Colorectal Cancer using Oxaliplatin and Coxsackievirus A11

A Novel Combination Therapy for Human Oxaliplatin-resistant Colorectal Cancer using Oxaliplatin and Coxsackievirus A11
Background: Colorectal cancer (CRC) is a major cause of morbidity and mortality throughout the world. It is the third most common cancer worldwide and the fourth most common cause of cancer-related death. FOLFOX, a combination of leucovorin calcium, fluorouracil, and oxaliplatin, is the first-line chemotherapy for stage III and stage IV CRC.
openaire  

Targeting the NAD+/SIRT1 axis: A metabolic strategy to overcome oxaliplatin resistance in colorectal cancer. [PDF]

World J Gastroenterol
Hussain MS, Jakhmola V, Goyal K, Rekha A, Sultana A, Ali H, Gupta G.   +6 more
europepmc   +1 more source